Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?

Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy? Publisher Pubmed

Seirafianpour F¹ ; Mozafarpoor S² ; Fattahi N³ ; Sadeghzadehbazargan A⁴ ; Hanifiha M^{3, 5} ; Goodarzi A⁴

Show Affiliations

1. Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2. Department of Dermatology, Skin Disease and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
3. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
4. Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
5. Children Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Dermatologic Therapy Published:2020

Abstract

The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine derivative and it inhibits the phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences, and Google Scholar up to 20 March 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, antifibrosis, oxygenation, circulation, bronchodilator, ARDS, and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline on controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for COVID-19 treatment, especially as an adjuvant therapy in combination with other drugs. © 2020 Wiley Periodicals LLC.

Related Docs

View other Related Docs

1. Pentoxifylline for Treatment of Major Depression After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2021)

2. Covid-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms, Journal of Molecular Histology (2020)

3. Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes, Diabetes Therapy (2022)

4. T Helper Type (Th1/Th2) Responses to Sars-Cov-2 and Influenza a (H1n1) Virus: From Cytokines Produced to Immune Responses, Transplant Immunology (2022)

5. Covid-19 Infection and Liver Injury: Clinical Features, Biomarkers, Potential Mechanisms, Treatment, and Management Challenges, World Journal of Clinical Cases (2021)

6. The Contributory Role of Lymphocyte Subsets, Pathophysiology of Lymphopenia and Its Implication As Prognostic and Therapeutic Opportunity in Covid-19, International Immunopharmacology (2021)

7. Positive Association Between Severity of Covid-19 Infection and Liver Damage: A Systematic Review and Meta-Analysis, Gastroenterology and Hepatology from Bed to Bench (2020)

8. Diffuse Alveolar Damage and Thrombotic Microangiopathy Are the Main Histopathological Findings in Lung Tissue Biopsy Samples of Covid-19 Patients, Pathology Research and Practice (2020)

Experts (# of related papers)

View all Related Experts

Amir Reza Radmard (1)

Leila Aghaghazvini (1)

Style	Citing Format
MLA	Seirafianpour F, et al.. "Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?." Dermatologic Therapy, vol. 33, no. 4, 2020, pp. -.
APA	Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadehbazargan A, Hanifiha M, Goodarzi A (2020). Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?. Dermatologic Therapy, 33(4), -.
Chicago	Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadehbazargan A, Hanifiha M, Goodarzi A. "Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?." Dermatologic Therapy 33, no. 4 (2020): -.
Harvard	Seirafianpour F et al. (2020) 'Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?', Dermatologic Therapy, 33(4), pp. -.
Vancouver	Seirafianpour F, Mozafarpoor S, Fattahi N, Sadeghzadehbazargan A, Hanifiha M, Goodarzi A. Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?. Dermatologic Therapy. 2020;33(4):-.
BibTex	@article{ author = {Seirafianpour F and Mozafarpoor S and Fattahi N and Sadeghzadehbazargan A and Hanifiha M and Goodarzi A}, title = {Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy?}, journal = {Dermatologic Therapy}, volume = {33}, number = {4}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Seirafianpour F AU - Mozafarpoor S AU - Fattahi N AU - Sadeghzadehbazargan A AU - Hanifiha M AU - Goodarzi A TI - Treatment of Covid-19 With Pentoxifylline: Could It Be a Potential Adjuvant Therapy? JO - Dermatologic Therapy VL - 33 IS - 4 SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract